Good evening :)
$
₹
Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

ARQT

NASDAQ
Asset Logo

Arcutis Biotherapeutics Inc

ARQT

NASDAQ
$25.510.51% (+0.13)
$
₹
$25.510.51% (+0.13)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $3.2B the stock is ranked 1793

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

115.36
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

14.47
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.22
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

6.15%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 7 analysts' reports

Buy
7 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +39.83% price upside over the next year

Current Price$25.51
Target Price$37

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
74.56
74.56
1Y Return
19.79%
19.79%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.98
23.98
1Y Return
38.66%
38.66%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
32.8%
32.8%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.58
29.58
1Y Return
31.31%
31.31%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.41
19.41
1Y Return
31.25%
31.25%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Arcutis Biotherapeutics Inc 115.3614.47-
AbbVie Inc74.5650.450.54
Amgen Inc23.9817.832.32

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

99.2
7.4
129.5
17.3
105.3
-11.2
129.8
15
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue49.5630.8544.7571.3665.8481.5099.21129.50105.39129.86
Net Income-35.38-52.33-41.53-10.78-25.06-15.887.4117.39-11.2915
Net Profit Margin-71.37%-169.58%-92.80%-15.11%-38.05%-19.49%7.46%13.43%-10.71%11.55%
See CostsAll values in $ Million

Frequently asked questions

  1. Arcutis Biotherapeutics Inc (ARQT) share price today is $25.51 as of September 21, 2026 at 8:31 PM IST. The stock touched a day high of $26.04 and a day low of $25.12.

  2. Arcutis Biotherapeutics Inc stock trades on NASDAQ under the ticker symbol ARQT.

  3. Arcutis Biotherapeutics Inc's market capitalization is $3.19B as of September 21, 2026 at 8:31 PM IST.

  4. Arcutis Biotherapeutics Inc's price-to-earnings (P/E) ratio is 115.36 as of September 21, 2026.

  5. Arcutis Biotherapeutics Inc's price-to-book (P/B) ratio is 14.47 as of September 21, 2026.

  6. Yes, You can buy Arcutis Biotherapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Arcutis Biotherapeutics Inc shares in three steps: 1. Search Arcutis Biotherapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Arcutis Biotherapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Arcutis Biotherapeutics Inc (ARQT) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.3919 shares at the current price of $25.51.

Loading...